Gene Therapy in Thalassemia and Hemoglobinopathies
2009

Gene Therapy for Thalassemia and Hemoglobin Disorders

publication Evidence: moderate

Author Information

Author(s): Breda Laura, Gambari Roberto, Rivella Stefano

Primary Institution: Weill College Medical Center, Department of Pediatrics, Division of Hematology-Oncology, NY, USA

Hypothesis

Can gene therapy effectively treat thalassemia and other hemoglobinopathies?

Conclusion

Gene therapy using lentiviral vectors shows promise in correcting hemoglobin disorders like thalassemia and sickle cell disease.

Supporting Evidence

  • Gene therapy has the potential to correct genetic defects in hemoglobin disorders.
  • Lentiviral vectors can deliver large genomic elements necessary for effective gene therapy.
  • Clinical trials are underway to test the efficacy of these gene therapy approaches.

Takeaway

Scientists are trying to fix blood disorders by changing genes in patients' cells, which could help them make healthy blood.

Methodology

The review discusses various gene therapy strategies, including the use of lentiviral vectors and gene editing techniques.

Potential Biases

There is a risk of insertional oncogenesis due to the integration of foreign genetic material.

Limitations

Current gene therapy approaches face challenges such as gene silencing and the need for improved delivery methods.

Participant Demographics

The disorders are common among Asian, African, African-American, and Mediterranean populations.

Digital Object Identifier (DOI)

10.4084/MJHID.2009.008

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication